ALECENSA 150MG Capsule- Apple Pharmaceuticals

Alecensa 150mg 

Alecensa 150mg belongs to a class of second-generation oral drug which specifically prevents Alecensa 150mg the  Alecensa 150mg activity Alecensa 150mg of anaplastic lymphoma kinase (ALK) tyrosine kinase.

Alecensa 150mg is a prescription drug which used under the guidance of a doctor.Alecensa 150mg
It is partly used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes the proliferation of NSCLC cells.

INDICATION:

Alecensa 150mg is used for the treatment of patients with anaplastic lymphoma kinase Alecensa 150mg (ALK) -Alecensa 150mgpositive metastatic non-small cell lung cancer (NSCLC).

DOSAGE MODIFICATION :

Non- Small Cell Lung Cancer
The usual dose is 600mg PO BID until disease progression or unacceptable
Renal impairment patients dose is 450mg orally twice daily
Alecensa is administrated with food.

MECHANISM

Particularly, crizotinib prevents anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, Alectinib is a type of tyrosine kinase inhibitor which targets ALK and RET. In nonclinical studies, Alectinib inhibits ALK phosphorylation and ALK-mediated activation of the downstream indicating proteins STAT3 and AKT and decreases tumor cell viability in multiple cell lines harboring ALK fusions, elaborations, or activating mutations.


Peak plasma concentration 4 hours and bioavailability of Alecensa 37%
Alectinib bound to human plasma proteins 99%
Metabolized by CYP3A4 to its major active metabolite M4, the main circulating moieties in plasma, total radioactivity 76% constituting.
In oral administration, radioactivity 98% was excreted in feces. 84% dose was excreted in the feces unchanged Alectinib.
Half-life is 33 hours.

PRECAUTION :

Embryo-fetal toxicity:
depends on data from animal studies and its pharmacological action, Alecensa can cause fetal harm when administered to pregnant women.
While Alecensa administration, Symptomatic bradycardia may have observed; control heart rate and blood pressure regularly
Alecensa may cause Severe myalgia and elevated CPK resulted; advise patients to report any unexplained muscle pain, tenderness, or weakness;
Renal impairment occurred during Alecensa treatment; the incidence of Grade ≥3 renal impairment was 1.7%, of which 0.5% were fatal events.

DRUG INTERACTION

No pharmacokinetic interactions with Alecensa 150mg needed dosage adjustment have been observed.

ALECENSA 150MG

CONTRAINDICATION

None.

MISSED DOSE

If the patient vomits after taking a dose of ALECENSA or missed to take a dose, they should not take an extra dose, but to take the next dose at the regular time, skip the missed dose.

STORAGE :

Store at below 30℃
Store the drug in the original container

SIDE EFFECTS:

Alecensa causes some side effects while administrating certain condition as follows :

COMMON SIDE EFFECTS :

Alecensa 150mg Muscle pain, Bradycardia, Tiredness, Constipation, Anemia , Hepatotoxicity, Feeling tired, Feeling less hungry than usual, Dark urine, Itchy skin, Nausea or vomiting, Abdominal Pain on the right side , Bleeding or bruising more easily than normal, Lung Problems, Trouble breathing, Shortness of breath , Cough, Fever .Alecensa 150mg





Phone : +91-9987711567
Email : applepharmaceutical@gmail.com
Email : info@myapplepharma.com
Website: applepharmaceuticals